The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study

Neuromuscular Disorders

Volumn 26, Issue 7, 2016, Pages 414-422

  Fischer, Dirk ^a,b,c   Hafner, Patricia ^a,b   Rubino, Daniela ^a   Schmid, Maurice ^a   Neuhaus, Cornelia ^a   Jung, Hans ^d   Bieri, Oliver ^c   Haas, Tanja ^c   Gloor, Monika ^c   Fischmann, Arne ^c,e   Bonati, Ulrike ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b University Clinic of Internal Medicine   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e Klinik St Anna   (Switzerland)

Author keywords

Becker muscular dystrophy; Dystrophinopathy; Imaging biomarker; Quantitative MR; Timed function tests

Indexed keywords

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; HUMAN; MIDDLE AGED; MOTOR PERFORMANCE; MUSCLE ATROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAXATION TIME; SIX MINUTE WALK TEST; YOUNG ADULT; ADIPOSE TISSUE; ADOLESCENT; AGE; DIAGNOSTIC IMAGING; DUCHENNE MUSCULAR DYSTROPHY; GENETICS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE; THIGH; WALK TEST; WALKING;

ADIPOSE TISSUE; ADOLESCENT; ADULT; AGE FACTORS; CROSS-SECTIONAL STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SEVERITY OF ILLNESS INDEX; THIGH; WALK TEST; WALKING; YOUNG ADULT;

EID: 84969242832     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2016.04.009     Document Type: Article

References (38)

1. [1] Kingston, H.M., Harper, P.S., Pearson, P.L., Davies, K.E., Williamson, R., Page, D., Localisation of gene for Becker muscular dystrophy. Lancet, 2, 1983, 1200.
2. [2] Bushby, K.M., Gardner-Medwin, D., Nicholson, L.V., et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 240 (1993), 105–112.
3. [3] Bushby, K.M., Gardner-Medwin, D., The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 240 (1993), 98–104.
4. [4] Anthony, K., Cirak, S., Torelli, S., et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134 (2011), 3547–3559.
5. [5] Beggs, A.H., Hoffman, E.P., Snyder, J.R., et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 49 (1991), 54–67.
6. [6] van den Bergen, J.C., Wokke, B.H., Janson, A.A., et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 85 (2014), 747–753.
7. [7] McDonald, C.M., Henricson, E.K., Abresch, R.T., et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48 (2013), 357–368.
8. [8] Brooke, M.H., Fenichel, G.M., Griggs, R.C., et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 6 (1983), 91–103.
9. [9] McDonald, C.M., Henricson, E.K., Han, J.J., et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41 (2010), 500–510.
10. [10] McDonald, C.M., Henricson, E.K., Han, J.J., et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42 (2010), 966–974.
11. [11] European Medicines Agency, Guideline on the clinical investigation of medicinal 4 products for the treatment of Duchenne and Becker 5 muscular dystrophy (draft). EMA/CHMP/738756/2011:1–17 www.ema.org, 2013.
12. [12] Vuillerot, C., Girardot, F., Payan, C., et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol 52 (2010), 60–65.
13. [13] Morrow, J.M., Sinclair, C.D., Fischmann, A., et al. Reproducibility, and age, body-weight and gender dependency of candidate skeletal muscle MRI outcome measures in healthy volunteers. Eur Radiol 24 (2014), 1610–1620.
14. [14] Wokke, B.H., Bos, C., Reijnierse, M., et al. Comparison of Dixon and T1-weighted MR methods to assess the degree of fat infiltration in Duchenne muscular dystrophy patients. J Magn Reson Imaging 38 (2013), 619–624.
15. [15] Brix, G., Heiland, S., Bellemann, M.E., Koch, T., Lorenz, W.J., MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy. Magn Reson Imaging 11 (1993), 977–991.
16. [16] Fischmann, A., Hafner, P., Fasler, S., et al. Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol 259 (2012), 1648–1654.
17. [17] Carlier, P.G., Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. Neuromuscul Disord 24 (2014), 390–392.
18. [18] Fischmann, A., Hafner, P., Gloor, M., et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 260 (2013), 969–974.
19. [19] Bonati, U., Hafner, P., Schadelin, S., et al. Quantitative muscle MRI: a powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord 25 (2015), 679–685.
20. [20] Morrow, J.M., Sinclair, C.D., Fischmann, A., et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 15 (2016), 65–77.
21. [21] Mazzone, E.S., Messina, S., Vasco, G., et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 19 (2009), 458–461.
22. [22] Bushby, K., Connor, E., Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 1 (2011), 1217–1235.
23. [23] Fischmann, A., Morrow, J.M., Sinclair, C.D., et al. Improved anatomical reproducibility in quantitative lower-limb muscle MRI. J Magn Reson Imaging 39 (2014), 1033–1038.
24. [24] Skinner, T.E., Glover, G.H., An extended two-point Dixon algorithm for calculating separate water, fat, and B0 images. Magn Reson Med 37 (1997), 628–630.
25. [25] Gaetano, J., Holm-Bonferroni sequential correction: an EXCEL calculator (1.1) [Microsoft Excel workbook]. https://www.researchgate.net/publication/236969037_Holm-Bonferroni_Sequential_Correction_An_EXCEL_Calculator.doi:10.13140/RG.2.1.4466.9927, 2013.
26. [26] Berard, C., Payan, C., Hodgkinson, I., Fermanian, J., A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 15 (2005), 463–470.
27. [27] Sinclair, C.D.J., Morrow, J.M., Yousry, T.A., et al. Inter-scan reproducibility of quantitative neuromuscular MRI. Neuromuscul Disord, 20, 2010, S28.
28. [28] Fischmann, A., Kaspar, S., Reinhardt, J., Gloor, M., Stippich, C., Fischer, D., Exercise might bias skeletal-muscle fat fraction calculation from Dixon images. Neuromuscul Disord 22:Suppl. 2 (2012), S107–10.
29. [29] Wokke, B.H., van den Bergen, J.C., Hooijmans, M.T., Verschuuren, J.J., Niks, E.H., Kan, H.E., T2 relaxation times are increased in skeletal muscle of DMD but not BMD patients. Muscle Nerve 53:1 (2016), 38–43.
30. [30] Monforte, M., Mercuri, E., Laschena, F., Ricci, E., Tasca, T., Calf muscle involvement in Becker muscular dystrophy: when size does not matter. J Neurol Sci 347 (2014), 301–304.
31. [31] Tasca, G., Iannaccone, E., Monforte, M., et al. Muscle MRI in Becker muscular dystrophy. Neuromuscul Disord 22:Suppl. 2 (2012), S100–6.
32. [32] Faridian-Aragh, N., Wagner, K.R., Leung, D.G., Carrino, J.A., MRI phenotyping of Becker muscular dystrophy. Muscle Nerve 50:6 (2014), 962–967.
33. [33] Wokke, B.H., Hooijmans, M.T., van den Bergen, J.C., Webb, A.G., Verschuuren, J.J., Kan, H.E., Muscle MRS detects elevated PDE/ATP ratios prior to fatty infiltration in Becker muscular dystrophy. NMR Biomed 27 (2014), 1371–1377.
34. [34] Bonati, U., Schmid, M., Hafner, P., et al. Longitudinal 2-point Dixon muscle magnetic resonance imaging in Becker muscular dystrophy. Muscle Nerve 51 (2015), 918–921.
35. [35] Bonati, U., Hafner, P., Schädelin, S., et al. Quantitative muscle MRI: a powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord, 2015, 10.1016/j.nmd.2015.05.006.
36. [36] Hollingsworth, K.G., de Sousa, P.L., Straub, V., Carlier, P.G., Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. Neuromuscul Disord 22:Suppl. 2 (2012), S54–67.
37. [37] Kan, H.E., Scheenen, T.W., Wohlgemuth, M., et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 19 (2009), 357–362.
38. [38] Azzabou, N., Loureiro de Sousa, P., Caldas, E., Carlier, P.G., Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J Magn Reson Imaging 41 (2015), 645–653.